We are live on ! Find out more
ACHL

Achilles Therapeutics
ACHL

Delisted

ACHL was delisted on the 20th of March, 2025.

Back to rankings

18 hedge funds and large institutions have $18.7M invested in Achilles Therapeutics in 2023 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 6 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 18 → 18 (0)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 3

3% less capital invested

Capital invested by funds: $19.4M → $18.7M (-$674K)

83% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 6

Holders
18
Holders Change
–
Holders Change %
0%
% of All Funds
0.28%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
3
Increased
1
Reduced
6
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$66K
2
VF
Virtu Financial
New York
+$15.9K
3
RJA
Raymond James & Associates
Florida
+$12.4K

Top Sellers

Rank Fund Capital Flow
1
Axa
Axa
France
-$270K
2
Morgan Stanley
Morgan Stanley
New York
-$200K
3
Millennium Management
Millennium Management
New York
-$84.4K
4
BBA
Baker Bros. Advisors
New York
-$32.5K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$13.3K
Name Holding Trade Value Shares
Change 		Change in
Stake
SP
1
Syncona Portfolio
Guernsey
$10.5M – – –
BBA
2
Baker Bros. Advisors
New York
$2.42M -$32.5K -34,217 -1%
AG
3
Artal Group
Luxembourg
$2.13M – – –
RG
4
Redmile Group
California
$1.52M – – –
Point72 Asset Management
5
Point72 Asset Management
Connecticut
$1.34M – – –
Renaissance Technologies
6
Renaissance Technologies
New York
$425K +$66K +69,500 +18%
EAM
7
EdenTree Asset Management
United Kingdom
$94.5K +$95K +100,000 New
FA
8
Forefront Analytics
Pennsylvania
$70.7K -$813 -856 -1%
Morgan Stanley
9
Morgan Stanley
New York
$68.8K -$200K -210,906 -74%
Citadel Advisors
10
Citadel Advisors
Florida
$63.2K -$383 -403 -0.6%
Millennium Management
11
Millennium Management
New York
$36.3K -$84.4K -88,880 -70%
Geode Capital Management
12
Geode Capital Management
Massachusetts
$20.4K – – –
VF
13
Virtu Financial
New York
$16K +$15.9K +16,790 New
RJA
14
Raymond James & Associates
Florida
$12.4K +$12.4K +13,096 New
Bank of America
15
Bank of America
North Carolina
$9.58K -$4.89K -5,153 -34%
JP Morgan Chase
16
JP Morgan Chase
New York
$935 – – –
Axa
17
Axa
France
– -$270K -282,028 Closed
Susquehanna International Group
18
Susquehanna International Group
Pennsylvania
– -$13.3K -13,900 Closed
UBS Group
19
UBS Group
Switzerland
– -$11.9K -12,379 Closed

ACHL Hedge Fund Activity: Q2 2023 in Review

18 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Achilles Therapeutics (ACHL) for Q2 2023, worth a combined $18.7M — down 3.5% from $19.4M a quarter earlier.

Fund positioning in ACHL was balanced in Q2 2023: 3 funds opened new positions, 3 closed out, 1 added to existing stakes and 6 trimmed.

The largest buyer was Renaissance Technologies, adding an estimated $66K. The largest seller was Axa, exiting entirely with an estimated $270K sold.

  • 18 institutional investors held Achilles Therapeutics (ACHL) as of Q2 2023, unchanged from Q1 2023.
  • Funds reported $18.7M of Achilles Therapeutics stock for Q2 2023, down 3.5% quarter-over-quarter.
  • 3 funds opened new Achilles Therapeutics positions in Q2 2023 and 3 closed out, a net change of 0 holders.
  • The largest Achilles Therapeutics buyer in Q2 2023 was Renaissance Technologies, an estimated $66K added.
  • The largest Achilles Therapeutics seller in Q2 2023 was Axa, an estimated $270K sold.

Based on aggregated 13F filings for Q2 2023.